← All trials
NCT04880512
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2021
- Primary completion
- Aug 20, 2022
- Completion date
- Dec 20, 2022
- First posted
- May 10, 2021
- Last posted
- Sep 30, 2021
- Enrollment
- 102
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yiling Pharmaceutical Inc.Lead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.